Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Aspen Pharmacare (APNHY) had Revenue of $2.39B for the most recently reported fiscal year, ending 2025-06-30.

Quarterly Annual

Figures for fiscal year ending 2025-06-30

Income Statement Financials
Revenue	$2.39B
Net Income	$-59.67M
Cost of Goods Sold	$1.34B
Gross Profit	$1.05B
Operating Expenses	$2.31B
Operating Income	$79.18M
Non-Operating Income/Expense	$-85.96M
Pre-Tax Income	$-6.78M
Normalized Pre-Tax Income	$-6.78M
Income after Taxes	$-59.67M
Income from Continuous Operations	$-59.67M
Consolidated Net Income/Loss	$-59.67M
Normalized Income after Taxes	$-59.67M
EBIT	$79.18M
EBITDA	$194.28M
Weighted-Average Shares Outstanding (Basic)	444.00M
Weighted-Average Shares Outstanding (Diluted)	444.00M
Earnings per Share (EPS) (Basic)	$-0.13
Earnings per Share (EPS) (Diluted)	$-0.13
Balance Sheet Financials
Current Assets	$2.13B
Property, Plant, and Equipment	$1.17B
Long-Term Assets	$5.36B
Total Assets	$7.49B
Current Liabilities	$964.03M
Long-Term Debt	$1.74B
Long-Term Liabilities	$1.85B
Total Liabilities	$2.81B
Common Equity	$4.68B
Tangible Shareholders Equity	$687.59M
Shareholders Equity	$4.68B
Common Shares Outstanding	444.02M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$284.26M
Cash Flow from Investing Activities	$-287.40M
Cash Flow from Financial Activities	$-8.93M
Beginning Cash	$397.82M
End Cash	$353.14M
Increase/Decrease in Cash	$-44.69M
Stock-Based Compensation	$6.01M
Common Stock Dividends Paid	$-88.22M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.27
Debt to Equity Ratio	0.43
Gross Margin	44.11%
Operating Margin	3.31%
EBIT Margin	3.31%
EBITDA Margin	8.13%
Pre-Tax Profit Margin	-0.28%
Profit Margin	-2.50%
Free Cash Flow	$144.20M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.32
Inventory Turnover	1.35
Receiveable Turnover	3.04
Days Sales in Receivables	120.23
Return on Equity	-1.28%
Return on Tangible Equity	-8.68%
Return on Assets	-0.80%
Return on Investments	-0.93%
Book Value Per Share	$10.53
Free Cash Flow per Share	$0.32
Operating Cash Flow per Share	$0.64

Data from Zacks Investment Research, Inc.